In the current study, NT-proBNP levels were elevated by >10% compared with the values at discharge in 60% of patients, exceeding those seen in the STRONG-HF trial (41.1%) while still achieving a high rate of QT (QT: 96% vs. 100%; p = 0.513; TD QT: 46% vs. 57%; p = 0.384; those exceeding the safety indicator vs. not exceeding the safety indicator for NT-proBNP). The gene discussed is NPPB; the disease is hydrops fetalis.